PresentationAt this time, I'd like to turn the call over to Greg Duncan, Chief Executive Officer for Dogwood Therapeutics. Please proceed, Mr. Duncan.Good morning, and welcome to today's Dogwood Therapeutics, Inc. Investor Call. [Operator Instructions] And please be advised that today's call is being recorded at the company's request.Greg DuncanChairman & CEO Thank you. Good morning all, and thank you for joining today's exciting investor call for Dogwood Therapeutics. I'm pleased to be joined by our Chief ...

Deepening our Commitment to Patients Suffering from Chemotherapy Induced Peripheral Neuropathy September 29th, 2025 NASDAQ: DWTX Agenda for Today Great Progress on Ongoing Halneuron® Phase 2b Chemotherapy Induced Pain Study Exciting New SP16 Cancer Related Pain Global License Overview Q&A NASDAQ: DWTX 2 Nav1.7 Research Pipeline Targeting Chronic and Acute Pain, Includes FDA Fast Track Designation for Treating CINP Target Indication Candidate/Target Preclinical Phase 1 Phase 2 Phase 3 Chemotherapy- Induced N ...